Robbins Headache Clinic Blog
“Who Will Get the Coronavirus Vaccine First?” from The New York Times
After months of deliberation and debate, a panel of independent experts advising the Centers for Disease Control and Prevention voted Tuesday to recommend that health care workers who are most at risk of contracting Covid-19, along with residents of nursing homes and...
“The Benefits of a Company Addressing Migraine at Work” from the American Migraine Foundation
How putting a program in place improved outcomes for employees with migraine Managing migraine at work can be hard for employees, but it also takes a toll on the company. That’s why Novartis, a global healthcare company based in Switzerland, launched a migraine...
“Light Therapy Lamps: What’s the Difference Between Cheap and Expensive Ones?” from The HuffPost
It’s not groundbreaking information that we’re all finding ourselves indoors more right now. Add that to the colder, darker days ahead and you may notice yourself feeling a little more moody or blue than usual. “Most people don’t think much about light on a day-to-day...
“Migraine Blogger Uses Her Brand to Advocate for Others” from American Migraine Foundation
Blogger Erica Carrasco discusses how her brand came to be and how she uses it to advocate for others Migraine advocacy takes many forms. There are real people behind this disease, each with their own lives and passions. In an effort to make a difference, some people...
“Vegetarian or Vegan? Watch Your Bone Health” from The New York Times
Those who ate a meat-free diet were at increased risk for bone fractures. Vegetarian diets are generally considered healthy, but new research suggests they may have a significant risk: an increased chance of bone fractures. Between 1993 and 2001, British researchers...
“So Many Migraine Therapies, So Many Decisions” from Migraine.com
Therapy options for patients with migraines have expanded over the past couple of years, with several new drug classes specific to the disorder. Leading migraine experts discuss how they decide to choose one therapy over another. Treatment options for migraine have...
“What Side Effects are People Experiencing with CGRP’s Now?” from Migraine.com
In 2018 the FDA approved three new medications to treat migraine.1 These medications are known by the brand names Aimovig, Emgality, and Ajovy. All three medications are in a class called calcitonin gene-related peptide inhibitors (CGRPs). CGRPs developed to treat...
“The Double Whammy of Seasonal Affective Disorder in a Season of Covid” from The New York Times
This winter the pandemic is expected to intensify the depression experienced by many people with the syndrome known as seasonal affective disorder, or SAD. We hadn’t yet switched back to standard time, with its shortened hours of afternoon daylight, when I began to...
“Nearly 80% of People Taking New Migraine Prevention Drugs Report Improvement” from Pain News Network
Nearly 80% of people taking a new class of medication to prevent migraine say their migraine headaches are “better” since they started taking the drugs, according to a survey conducted by Eli Lilly. Calcitonin gene-related peptide (CGRP) inhibitors prevent migraines...
“In 2020, Self-Care is Becoming a More Radical Act” from the HuffPost
Amid a global pandemic, climate change, racial unrest and a 24/7 news cycle, self-care is no longer a luxury — it’s a necessity. Collective stress and anxiety have surged in 2020. Almost 50% percent of Americans between the ages of 18 and 29 said they’ve...